Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase I/II study of preoperative treatment with XELOXIRI(CPT-11, L-OHP, capecitabine) with Cetuximab in patients with RAS wild type-advanced colorectal cancer

ABSTRACT: Interventions: Neo-adjuvant chemotherapy : XELOXIRI with Cetuximab 4 cycles Resection : total mesorectal excision or tumor-specific mesorectal excision Adjuvant chemotherapy : XELOX 4 cycles Primary outcome(s): 1) Phase I To determine the recommended dose 2) Phase II pathological complete response rate Study Design: Single arm Non-randomized

DISEASE(S): Locally Advanced Rectal Cancer

PROVIDER: 2647905 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase I/II study of preoperative treatment with capecitabine, oxaliplatin and irinotecan (XELOXIRI) in patients with advanced colorectal cancer

Project description:Interventions: Neo-adjuvant chemotherapy : XELOXIRI 6 cycles Resection : total mesorectal excision or tumor-specific mesorectal excision Adjuvant chemotherapy : XELOX 4 cycles Primary outcome(s): 1) Phase I To determine the recommended dose 2) Phase II pathological complete response rate Study Design: Single arm Non-randomized

| 2625365 | ecrin-mdr-crc

Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer

Project description:RATIONALE: 5FU based neoadjuvant chemoradiation (nCRT) is the standard of care for Stage II/III rectal cancer. Pathologic complete response (pCR) and downstaging have been associated with improved outcomes. The addition of oxaliplatin (OXA) to neoadjuvant therapy may reduce distant disease recurrence. Adjuvant treatment with OXA for rectal cancer has been motivated by benefits demonstrated in stage III colon cancer. Objective: To determine the feasibility, toxicity, and efficacy of preoperative OXA/5FU and RT followed by total mesorectal excision (TME) and adjuvant PURPOSE: This phase II trial is studying the side effects and how well giving neo-adjuvant combination chemotherapy with radiation works in treating patients undergoing surgery for rectal cancer.

| 2066999 | ecrin-mdr-crc

Phase I study of XELOXIRI(CPT-11,L-OHP, capecitabine) with Bevacizumab in patients with unresectable advanced/metastatic colorectal cancer

Project description:Interventions: Patients receive infusional CPT-11,L-OHP, bevacizumab, and oral capecitabine every 21 days. Primary outcome(s): Safety Study Design: Single arm Non-randomized

| 2620878 | ecrin-mdr-crc

Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers [ATAC melanoma]

Project description:ATAC-seq was used to study the chromatin landscape of CD8 T cells in locally advanced melanoma patients treated with neo-adjuvant/adjuvant Pembrolizumab

2022-03-08 | GSE179606 | GEO

Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers [RNA melanoma]

Project description:RNA-seq was used to study the transcriptional landscape of CD8 T cells in locally advanced melanoma patients treated with neo-adjuvant/adjuvant Pembrolizumab.

2022-03-08 | GSE179612 | GEO

Gene expression profiling of 60 pre-chemotherapy FFPE endoscopic oesophageal adenocarcinoma biopsies

Project description:Oesophageal cancer is the ninth most common cancer in the UK and accounts for 5% of all cancer deaths. The incidence of the disease in men has risen 50% in the last 25 years with the commonest pathological subtype in the West being adenocarcinoma, while in East Asia oesophageal squamous cell carcinoma predominates. Despite efforts to screen for Barrett’s oesophagus, and pre-operatively select OAC patients who are likely to benefit from potentially curative surgery, survival remains poor. The five year survival rate is less than 17% and even in early stage locoregional confined disease this figure lies between 25-35%. A significant improvement in overall survival has been demonstrated with neo-adjuvant or peri-operative chemotherapy but the optimal approach for individual patients remains unclear. A consistent finding has been that complete histopathological response to neo-adjuvant chemotherapy is a prognostic biomarker for increased survival benefit. Therefore, there is a pressing need to identify biomarkers capable of predicting response, enabling clinicians to select patients for whom neo-adjuvant therapies would be beneficial. This experiment represents gene expression profiling of 60 pre-treatment formalin-fixed paraffin embedded (FFPE) oesophageal adenocarcinoma biopsies. All patients were treated with neo-adjuvant cisplatin-based chemotherapy prior to surgical resection at the Northern Ireland Cancer Centre from 2004-2012. The aim of the experiment was to carry out functional enrichment of pathological responders and non-responders to neo-adjuvant chemotherapy in order to identify novel mechanism of drug resistance or chemo-sensitivity.

2018-05-10 | E-MTAB-4666 | biostudies-arrayexpress

Expression data from MT-ret tumor tissue

Project description:Expression analysis of total MT-ret tumor RNA upon neo-adjuvant Ang2 targeting

2020-12-01 | GSE141127 | GEO

Voorbehandeling met chemotherapie, verwarmde buikspoeling met chemotherapie na chirugische verwijdering van alle tumor bij patienten met buikvlies uizaaiingen van dikke darm of endeldarm kanker.

Project description:Interventions: Neo-adjuvant chemotherapy giving six cycles of oxaliplatin and capecitbine preoperatively followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using mitomycin C. Primary outcome(s): Efficacy of neo-adjuvant chemotherapy with respect to the percentage of patients who are resectable after neo-adjuvant chemotherapy. Study Design: N/A: single arm study, Open (masking not used), N/A , unknown, Factorial

| 18100 | ecrin-mdr-crc